|
|
|
| Research progress on the relationship between fibroblast growth factor 21 and gestational diabetes mellitus |
| ZHANG Qian1 LI Qin2 |
1.The Second Clinical, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712046, China;
2.the Sixth Departments of Gynecology, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712099, China |
|
|
|
Abstract Gestational diabetes mellitus (GDM) is a common pregnancy disease in obstetrics and gynecology. GDM is associated with adverse perinatal outcomes and long-term prognosis of mother and baby. Fibroblast growth factor (FGF) 21, a member of the FGF family, plays an important role in glucose metabolism and lipid metabolism. FGF21 can improve insulin sensitivity, increase glucose uptake in tissues and organs, and play a role in reducing blood glucose. The feasibility of FGF21 as a new blood glucose control drug has become a hot topic in recent years. In this paper, the structural characteristics and physiological functions of FGF21, as well as the research status and application prospect of FGF21 in patients with GDM are summarized. High serum level of FGF21 in pregnant women can be used as a predictor of GDM, and stage analogues have broad research prospects in the treatment of GDM.
|
|
|
|
|
|
[1] American Diabetes Association. 2. Classification and Diagnosis of Diabetes：Standards of Medical Care in Diabetes-2021 [J]. Diabetes Care，2021，44（S1）：S15-S33.
[2] Vounzoulaki E，Khunti K，Abner SC，et al. Progression to type 2 diabetes in women with a known history of gestational diabetes：systematic review and meta-analysis [J]. BMJ，2020，369：m1361.
[3] Nguyen CL，Pham NM，Binns CW，et al. Prevalence of Gestational Diabetes Mellitus in Eastern and Southeastern Asia：A Systematic Review and Meta-Analysis [J]. J Diabetes Res，2018，2018：6536974.
[4] Szczepańska E，Gietka-Czernel M. FGF21：A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance [J]. Horm Metab Res，2022，54（4）：203-211.
[5] She QY，Bao JF，Wang HZ，et al. Fibroblast growth factor 21：A“rheostat”for metabolic regulation？[J]. Metabolism，2022，130：155166.
[6] Talukdar S，Zhou Y，Li D，et al. A Long-Acting FGF21 Mol- ecule，PF-05231023，Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects [J]. Cell Metab，2016，23（3）：427-440.
[7] Owen BM，Ding X，Morgan DA，et al. FGF21 acts centrally to induce sympathetic nerve activity，energy expenditure，and weight loss [J]. Cell Metab，2014，20（4）：670-677.
[8] Beenken A，Mohammadi M. The structural biology of the FGF19 subfamily [J]. Adv Exp Med Bio，2012，728：1-24.
[9] Suzuki M，Uehara Y，Motomura-Matsuzaka K，et al. betaKlotho is required for fibroblast growth factor（FGF）21 signaling through FGF receptor（FGFR）1c and FGFR3c [J]. Mol Endocrinol，2008，22（4）：1006-1014.
[10] Potthoff MJ，Kliewer SA，Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21：from feast to famine [J]. Genes Dev，2012，26（4）：312-324.
[11] Markan KR，Naber MC，Ameka MK，et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding [J]. Diabetes，2014，63（12）：4057- 4063.
[12] Keipert S，Ost M，Johann K，et al. Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine [J]. Am J Physiol Endocrinol Metab，2014，306（5）：E469-E482.
[13] Li H，Fang Q，Gao F，et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride [J]. J Hepatol，2010，53（5）：934-940.
[14] Lan T，Morgan DA，Rahmouni K，et al. FGF19，FGF21，and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia [J]. Cell Metab，2017，26（5）：709-718.e3.
[15] Véniant MM，Hale C，Helmering J，et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice [J]. PLoS One，2012，7（7）：e40164.
[16] Klaebel JH，Lykkesfeldt J，Tveden-Nyborg P. Efficacy of fibroblast growth factor 21 in non-alcoholic fatty liver disease in guinea pigs [J]. Basic Clin Pharmacol Toxicol，2022，130（3）：385-393.
[17] Geng L，Lam KSL，Xu A. The therapeutic potential of FGF21 in metabolic diseases：from bench to clinic [J]. Nat Rev Endocrinol，2020，16（11）：654-667.
[18] Sanyal A，Charles ED，Neuschwander-Tetri BA，et al. Pegbelfermin（BMS-986036），a PEGylated fibroblast growth factor 21 analogue，in patients with non-alcoholic steatohepatitis：a randomised，double-blind，placebo-controlled，phase 2a trial [J]. Lancet，2019，392（10165）：2705-2717.
[19] Rusza?覥a M，Pilszyk A，Niebrzydowska M，et al. Novel Biom- olecules in the Pathogenesis of Gestational Diabetes Mellitus 2.0 [J]. Int J Mol Sci，2022，23（8）：4364.
[20] ?譒imják P，Cinkajzlová A，Anderlová K，et al. Changes in plasma concentrations and mRNA expression of hepatokines fetuin A，fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus [J]. Physiol Res，2018，67（S3）：S531-S542.
[21] Wang Z，Yuan M，Xu C，et al. FGF21 Serum Levels in the Early Second Trimester Are Positively Correlated With the Risk of Subsequent Gestational Diabetes Mellitus：A Propensity-Matched Nested Case-Control Study [J]. Front Endocrinol（Lausanne），2021，12：630287.
[22] Durnwald C，Mele L，Landon MB，et al. Fibroblast Growth Factor 21 and Metabolic Dysfunction in Women with a Prior Glucose-Intolerant Pregnancy [J]. Am J Perinatol，2021，38（13）：1380-1385.
[23] Sutton EF，Morrison CD，Stephens JM，et al. Fibroblast growth factor 21，adiposity，and macronutrient balance in a healthy，pregnant population with overweight and obesity [J]. Endocr Res，2018，43（4）：275-283.
[24] Zhang J，Li Y. Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders [J]. Front Endocrinol（Lausanne），2015，6：168.
[25] Megia A，Gil-Lluis P，N?覿f S，et al. Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth [J]. Acta Diabetol，2015，52（4）：693-700.
[26] Kampmann FB，Thuesen ACB，Hjort L，et al. Increased leptin，decreased adiponectin and FGF21 concentrations in adolescent offspring of women with gestational diabetes [J]. Eur J Endocrinol，2019，181（6）：691-700.
[27] Fisher FM，Maratos-Flier E. Understanding the Physiology of FGF21 [J]. Annu Rev Physiol，2016，78：223-241.
[28] Kharitonenkov A，Beals JM，Micanovic R，et al. Rational design of a fibroblast growth factor 21-based clinical candidate，LY2405319 [J]. PLoS One，2013，8（3）：e58575.
[29] Maeng HJ，Lee GY，Bae JH，et al. Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model [J]. Int J Mol Sci，2020，21（18）：6836.
[30] Adams AC，Halstead CA，Hansen BC，et al. LY2405319，an Engineered FGF21 Variant，Improves the Metabolic Status of Diabetic Monkeys [J]. PLoS One，2013，8（6）：e65763.
[31] Struik D，Dommerholt MB，Jonker JW. Fibroblast growth factors in control of lipid metabolism：from biological function to clinical application [J]. Curr Opin Lipidol，2019，30（3）：235-243.
[32] Huang Z，Wang H，Lu M，et al. A better anti-diabetic recombinant human fibroblast growth factor 21（rhFGF21）modified with polyethylene glycol [J]. PLoS One，2011，6（6）：e20669.
[33] Xu P，Ye X，Zhang Y，et al. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes [J]. J Diabetes Complications，2015，29（1）：5-12
[34] Dirksen A，Davis KA，Collins JT，et al. Process development of a FGF21 protein-antibody conjugate [J]. Biopolymers，2017，110（1）：e23042 |
|
|
|
